Fig. 3. Anti-tumor efficacy of OVA/CHP nanogel vaccine with anti-PD-1 antibody. E.G7-OVA tumor-bearing mice (n = 6–8) were treated with vaccines and anti-PD-1 antibody. (A) E.G7-OVA tumor volumes in mice treated with anti-PD-1 antibody, OVA, OVA with anti-PD-1 antibody, OVA/CHP nanogel vaccine, or OVA/CHP nanogel vaccine with anti-PD-1 antibody. (B) Survival rates of the mice. Data are shown as means ± SEM. *p < 0.05, **p < 0.01, by one-way ANOVA (A) or log-rank (Mantel–Cox) test (B).
